Progression Rates of Diabetic Retinal Disease: A 20-Year Analysis

Recent research from the ARVO 2026 meeting in Denver investigated the progression rates of diabetic retinal disease (DRD) and vision-threatening diabetic retinopathy (VTDR) between 2003 and 2022. The study analyzed data from large commercial and Medicare Advantage health plans using ICD-9 and ICD-10 codes. Its primary aim was to assess the likelihood of progression to conditions like DRD, VTDR, diabetic macular edema (DME), and proliferative diabetic retinopathy (PDR) among patients with diabetes mellitus sans previous diabetic retinal disease.

Among 4.2 million patients observed, approximately 5.6% developed diabetic retinal disease, with smaller percentages advancing to more severe forms: 1.7% to VTDR, 1.0% to DME, and 0.76% to PDR. The findings revealed a notable decrease in the hazard for progression of these conditions over the two decades, with significant declines post-2011. Adjusted hazard ratios showed that by 2011, the risk for diabetic retinal disease had diminished by 38% compared to 2002, stabilizing at 13% lower by 2022. For VTDR, DME, and PDR, risk reductions of 56%, 47%, and 67% respectively were observed by 2022.

Overall, advancements in diabetes care have contributed to reducing progression to severe retinal disorders, highlighting improved management strategies over the observed timeframe. This underscores the critical need for continuous evaluation of diabetic care protocols to mitigate risks of severe retinal complications effectively.